Search research articles
Contact Us
Filters
Showing results (61-70 of 81) with videos related to
Page
of 9
Sort By:
Clinical and Translational Science
|
December 8, 2020
Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF-06826647: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study
Ravi Shankar P Singh, Vivek Pradhan, Erika S Roberts, et al.
Journal of the American Academy of Dermatology
|
March 24, 2021
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
Brett King, Emma Guttman-Yassky, Elena Peeva, et al.
The Journal of Investigative Dermatology
|
January 24, 2020
Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis
Karen M Page, Mayte Suarez-Farinas, Maria Suprun, et al.
Experimental Dermatology
|
September 20, 2024
Efficacy and safety of ritlecitinib in vitiligo patients across Fitzpatrick skin types with biomarker analyses
Elena Peeva, Yuji Yamaguchi, Zhan Ye, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
January 9, 2023
Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study
William J Sandborn, Silvio Danese, Jaroslaw Leszczyszyn, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
May 17, 2023
Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial
Philip Mease, Philip Helliwell, Paula Silwinska-Stanczyk, et al.
Dermatitis : Contact, Atopic, Occupational, Drug
|
April 2, 2021
Patient-Reported Symptoms and Disease Impacts in Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 2b Study With Abrocitinib
Eric L Simpson, Andreas Wollenberg, Robert Bissonnette, et al.
The Journal of Dermatology
|
September 27, 2024
Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis
Natasha Mesinkovska, Brett King, Xingqi Zhang, et al.
Journal of Crohn'S & Colitis
|
December 23, 2023
Baseline Serum and Stool Microbiome Biomarkers Predict Clinical Efficacy and Tissue Molecular Response After Ritlecitinib Induction Therapy in Ulcerative Colitis
Mina Hassan-Zahraee, Zhan Ye, Li Xi, et al.
Dermatology and Therapy
|
December 31, 2020
Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD
Rebecca Hall, Mark G Lebwohl, Andrew G Bushmakin, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 81) with videos related to
Sort By:
Page
of 9
Clinical and Translational Science
|
December 8, 2020
Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF-06826647: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study
Ravi Shankar P Singh, Vivek Pradhan, Erika S Roberts, et al.
Journal of the American Academy of Dermatology
|
March 24, 2021
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
Brett King, Emma Guttman-Yassky, Elena Peeva, et al.
The Journal of Investigative Dermatology
|
January 24, 2020
Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis
Karen M Page, Mayte Suarez-Farinas, Maria Suprun, et al.
Experimental Dermatology
|
September 20, 2024
Efficacy and safety of ritlecitinib in vitiligo patients across Fitzpatrick skin types with biomarker analyses
Elena Peeva, Yuji Yamaguchi, Zhan Ye, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
January 9, 2023
Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study
William J Sandborn, Silvio Danese, Jaroslaw Leszczyszyn, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
May 17, 2023
Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial
Philip Mease, Philip Helliwell, Paula Silwinska-Stanczyk, et al.
Dermatitis : Contact, Atopic, Occupational, Drug
|
April 2, 2021
Patient-Reported Symptoms and Disease Impacts in Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 2b Study With Abrocitinib
Eric L Simpson, Andreas Wollenberg, Robert Bissonnette, et al.
The Journal of Dermatology
|
September 27, 2024
Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis
Natasha Mesinkovska, Brett King, Xingqi Zhang, et al.
Journal of Crohn'S & Colitis
|
December 23, 2023
Baseline Serum and Stool Microbiome Biomarkers Predict Clinical Efficacy and Tissue Molecular Response After Ritlecitinib Induction Therapy in Ulcerative Colitis
Mina Hassan-Zahraee, Zhan Ye, Li Xi, et al.
Dermatology and Therapy
|
December 31, 2020
Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD
Rebecca Hall, Mark G Lebwohl, Andrew G Bushmakin, et al.
Page
of 9